To further probe this relationship, we performed western blot analysis on seven CLL patient samples and observed decreased expression of tristetrapolin (ZFP36), a key regulator of ARE-bearing mRNA degradation, with VIP152 treatment (Fig. 3E, F). Here, ZFP36 is linked to B-cell chronic lymphocytic leukemia.